Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLTNHY)

Drug Name

Acetic Acid Salicyloyl-Amino-Ester Drug Info

Synonyms

O-Acetylsalicylhydroxamic Acid; ACETIC ACID SALICYLOYL-AMINO-ESTER; 199854-00-7; C9H9NO4; O-Acetyl Salicylhydroxamic Acid; N-(Acetyloxy)-2-hydroxybenzamide; SCL; N-Acetoxysalicylamide; AC1L9HR3; SCHEMBL4318044; CTK0A0021; PCFWLDHLJWUGSU-UHFFFAOYSA-N; MolPort-003-844-411; [(2-hydroxybenzoyl)amino] acetate; ZINC2046853; FCH850362; 1962AH; Benzamide, N-(acetyloxy)-2-hydroxy-; AKOS006293238; DB03667; AB22745; ACM199854007; (2-HYDROXYPHENYL)FORMAMIDO ACETATE; RT-014810; FT-0661357; 1846-EP2298783A1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 445302
TTD Drug ID: DMLTNHY

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[2]
Naproxen	DMZ5RGV	Bursitis		Approved	[3]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[4]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[5]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[6]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[7]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[8]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[7]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[9]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
3	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
4	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
6	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
9	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
10	Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.